[
フレーム]
Please make JavaScript on and see this site.
Back
-
Regulations & Services of PMDA
Information about Approved Products in Japan
-
Information for approved products in Japan
-
Development of Drugs, Medical devices, Regenerative medicines and in Vitro diagnostics
Information for approved products in Japan
-
Regulations and services of PMDA
Information for approved products in Japan
Back
-
Regulations and Services of PMDA
Information for apporoved products in Japan
-
Regulations and Services of PMDA
Information for apporoved products in Japan
-
Reviews and Related Services
Post-marketing Safety Measures
-
Reviews and Related Services
Post-marketing Safety Measures
Regulatory Science/The Science Board/Standard Development
The 2nd Subcommittee on Therapeutic Products Based on Extracellular Vesicles (EVs) Including Exosomes
Press Release
October 4, 2021 from 2pm to 3:45pm
Given the impact of COVID-19, the conference was held online.
Agenda / List of Handouts
Agenda
- Lecture by Subcommittee Member and Discussion
- Drug Discovery Based on the Murine POC (An Example Using Cytotoxic T Lymphocyte EVs) (Special Lecturer SEO, Member of the Subcommittee)
- Possibilities and Problems of Engineered Exosomes (Professor HANAYAMA, Vice Chairperson of the Subcommittee)
- Issues and Assignment Table of Report on Therapeutic Products Based on Extracellular Vesicles (EVs) Including Exosomes
- Others
List of Handouts
- Document 1 Lecture Material by Special Lecturer SEO (Member of the Subcommittee)
- Document 2 Lecture Material by Professor HANAYAMA (Vice Chairperson of the Subcommittee)
- Document 3 Lecture Material by Professor TAKAKURA (Chairperson of the Subcommittee)
- Ref.1 Letter to the Editor Published in British Journal of Clinical Pharmacology https://doi.org/10.1111/bcp.15065